Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) Stock Information | RedChip
Image

ASK REDCHAT ANYTHING ABOUT QUOIN PHARMACEUTICALS LTD.

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX)
Listen to this Section


$4.40
-0.0300 ( -0.68% ) 18.0K

Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.

Clinical Trial Pipeline Stages


Drug Name Stage
QRX003DetailsNetherton syndrome Phase 3
QRX003DetailsSkin disease/disorder, Rare genetic disease, Peeling skin syndrome Phase 1

Market Data


Open $4.40
Previous Close $4.43
Volume 18.0K
Market Cap $8.90M
Day Range $4.31 - $4.85
52 Week Range $4.11 - $41.80
Shares Outstanding 2.01M
Change % -0.68%
Net Change ▼ -0.0300
Insider Ownership -0.03%
Exchange NASDAQ
SectorHealthcare
IndustryMedical/Dental Instruments
IPO Year2021
CountryIsrael

Insider Ownership Transactions

Total Amount Purchased: 1,100,326.00

Date Type Amount Purchased Purchaser
2025-10-15 Buy 15152.00 LANGER DENNIS
2024-12-27 Buy 555556.00 Myers Michael
2024-12-27 Buy 100000.00 Culverwell Anthony James
2024-12-27 Buy 122221.00 Dunn Gordon
2024-12-27 Buy 555556.00 Carter Denise P.
2024-09-11 Buy 856.00 Dunn Gordon
2024-09-05 Buy 800.00 Myers Michael
2024-09-05 Buy 1822.00 Carter Denise P.
2024-06-10 Sale -297.00 LANGER DENNIS
2023-10-30 Sale -51149.00 Dunn Gordon

SEC Filings


Form Type Description Pages Date
8-k 8K-related 13 Nov 12, 2025
10-q Quarterly Reports 74 Nov 06, 2025
8-k 8K-related 13 Nov 06, 2025
8-k 8K-related 13 Oct 21, 2025
8-k 8K-related 20 Oct 15, 2025
4 Insider transactions 1 Oct 15, 2025
3 Insider transactions 2 Sep 08, 2025
8-k 8K-related 13 Aug 27, 2025
4 Insider transactions 1 Aug 25, 2025
4 Insider transactions 1 Aug 25, 2025

Latest News


× Before browsing our site, please accept our cookies policy